Navigation Links
Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
Date:1/10/2011

HORSHAM, Pa., Jan. 10, 2011 /PRNewswire/ -- Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company focused on dermatology and pediatrics, today announced that Mark Strobeck, Ph.D., has been appointed vice president and chief business officer. In his new role Dr. Strobeck will report to Robert Radie, president and chief executive officer, and will be responsible for managing business development, corporate strategy and financings.

"We are pleased to welcome to the Topaz management team Mark, a proven leader with a significant track record of success, who will lead our business development efforts," said Robert Radie, president and chief executive officer of Topaz. "With our lead product candidate nearing the final stage of development, we are building our commercial capabilities and interested in extending our business development reach."

Dr. Strobeck has decades of experience in the pharmaceutical and financial industry. Most recently, he served as chief business officer of Trevena, Inc., a pharmaceutical company dedicated to the discovery and development of GPCR biased ligands. Before joining Trevena he served as vice president of business development at GlaxoSmithKline (GSK) where he led the business development efforts for the company's clinical and preclinical stage assets. He also served as vice president of business development for the center of excellence for external drug discovery, a research and development division within GSK. Prior to this role Dr. Strobeck was a principal at SR One Ltd., the wholly owned venture capital arm of GSK.

Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati. He completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and has a bachelor's degree from St. Lawrence University.

About Topaz Pharmaceuticals Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for pediatric and dermatology markets. The company's lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice in children and adults which affects between six and 12 million people every year. The company has recently concluded two phase 3 studies of ivermectin for this potential indication and expects to file a new drug application this year. Topaz, headquartered in Horsham, PA, is backed by top-tier investors including Aisling Capital and Fidelity Biosciences. For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com. Contact Information E. Blair Schoeb Tel: 908-277-0386 blair@biotechcomm.com
'/>"/>

SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
4. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
5. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
6. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. TOPAZ Technologies and ML Weekes & Company Announce Partnership
8. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
9. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of year ... Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer ... Cundiff. , “We are honored to support a promising young investigator from Dr. Lengyel’s ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... World Molecular Imaging Congress (WMIC), will be held in New York City, NY ... “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Early this week, ... and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from ... cocoa farmers and the quality of their product, through activities that focus on better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
Breaking Medicine News(10 mins):